Luke O’Neill joins Open Orphan spin-off ahead of pharma firm’s IPO
Ambitions are high for Poolbeg Pharma, which will develop drugs to fight infectious diseases
Luke O’Neill, the well-known immunologist, has joined the board of the fledgling Poolbeg Pharma which is preparing for a stock market launch in coming weeks.
Poolbeg Pharma is a newly launched spin-off of Open Orphan, the life sciences business co-founded by veteran financier Cathal Friel, and will specialise in developing drugs to treat infectious diseases.
O’Neill is a non-executive director and a member of the company’s scientific advisory board.
Subscribe from just €1 for the first month!
With any subscription you will have access to
Unlimited multi-device access to our iPad, iPhone and Android Apps
Unlimited access to our eReader library
Exclusive daily insight and opinion seven days a week
Create alerts to never miss a subject that matters to you
Get access to exclusive offers for subscribers on gifts and experiences
Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine
Pinterest doubles Irish workforce as revenues surge by €100m
Despite positive returns, social media company warns of ‘headwinds’ to use of its platform as pandemic restrictions lift
Turnover down 50% at River Island as pandemic hits in-store trading
The clothing company reduced its staff headcount by more than 100 during 2020 as the pandemic closed its stores for a third of the year
Nestlé cuts value of stake in shrinking infant formula arm by €260m
The global food company has significantly reduced the value of its investments in Wyeth Nutritionals over the past two years as production at the Askeaton company has fallen off
US medtech behemoth signals intent to commit to Ireland
Edwards Lifesciences says it will continue doing business in this country despite the coming hike in corporation tax